Abstract:Ethnopharmacological relevance: The limitations of modern medicine in mitigating the pathological process of diabetic kidney disease (DKD) necessitate novel, precise, and effective prevention and treatment methods. Huangqi, the root of Astragalus membranaceus Fisch. ex Bunge has been used in traditional Chinese medicine for various kidney ailments. Astragaloside IV (AS-IV), the primary pharmacologically active compound in A. membranaceus, is involved in lipid metabolism regulation; however, its potential in ameliorating renal damage in DKD remains unexplored. Aim of the study: To elucidate the specific mechanism by which AS-IV moderates DKD progression. Materials and methods: A murine model of DKD and high glucose-induced HK-2 cells were treated with AS-IV. Furthermore, multiomics analysis, molecular docking, and molecular dynamics simulations were performed to elucidate the mechanism of action of AS-IV in DKD, which was validated using molecular biological methods. Results: AS-IV regulated glucose and lipid metabolism in DKD, thereby mitigating lipid deposition in the kidneys. Proteomic analysis identified 12 proteins associated with lipid metabolism regulated by AS-IV in the DKD renal tissue. Additionally, lipid metabolomic analysis revealed that AS-IV upregulated and downregulated 4 beneficial and 79 harmful lipid metabolites, respectively. Multiomics analysis further indicated a positive correlation between the top-ranked differential protein heme oxygenase (HMOX)1 and the levels of various harmful lipid metabolites and a negative correlation with the levels of beneficial lipid metabolites. Furthermore, enrichment of both ferroptosis and hypoxia-inducible factor (HIF)-1 signaling pathways during the AS-IV treatment of DKD was observed using proteomic analysis. Validation results showed that AS-IV effectively reduced ferroptosis in DKD-affected renal tubular epithelial cells by inhibiting HIF-1α/HMOX1 pathway activity, upregulating glutathione peroxidase-4 and ferritin heavy chain-1 expression, and downregulating acyl-CoA synthetase long-chain family member-4 and transferrin receptor-1 expression. Our findings demonstrate the potential of AS-IV in mitigating DKD pathology by downregulating the HIF-1α/HMOX1 signaling pathway, thereby averting ferroptosis in renal tubular epithelial cells. Conclusions: AS-IV is a promising treatment strategy for DKD via the inhibition of ferroptosis in renal tubular epithelial cells. The findings of this study may help facilitate the development of novel therapeutic strategies.

Astragaloside IV-mediated inhibition of oxidative stress by upregulation of ghrelin in type 2 diabetes-induced cognitive impairment

Astragaloside IV supplementation attenuates cognitive impairment by inhibiting neuroinflammation and oxidative stress in type 2 diabetic mice

Effect of Astragaloside IV on Hepatic Glucose‐regulating Enzymes in Diabetic Mice Induced by a High‐fat Diet and Streptozotocin

Carnosine-based reversal of diabetes-associated cognitive decline via activation of the Akt/mTOR pathway and modulation of autophagy in a rat model of type 2 diabetes mellitus

Effect and Mechanism of Auricularia Auriculajudae Polysaccharide in Hippocampus of Streptozotocin‐induced Diabetic Cognitive Impairment Rats

Astragaloside IV Prevents Memory Impairment in D-galactose-induced Aging Rats Via the AGEs/RAGE/ NF-κB Axis

Chronic Ghrelin Administration Suppresses IKK/NF-κB/BACE1 Mediated Aβ Production in Primary Neurons and Improves Cognitive Function Via Upregulation of PP1 in STZ-diabetic Rats

Astragaloside IV Promotes the Enos/no/cgmp Pathway and Improves Left Ventricular Diastolic Function in Rats with Metabolic Syndrome.

Astragaloside IV Ameliorates Motor Deficits and Dopaminergic Neuron Degeneration Via Inhibiting Neuroinflammation and Oxidative Stress in a Parkinson's Disease Mouse Model.

Anti-Apoptosis Effect of Astragaloside Iv on Alzheimer's Disease Rat Model Via Enhancing the Expression of Bcl-2 and Bcl-Xl

Astragaloside IV Ameliorates Streptozotocin Induced Pancreatic β-Cell Apoptosis and Dysfunction Through SIRT1/P53 and Akt/GSK3β/Nrf2 Signaling Pathways

Astragaloside IV Ameliorates Cognitive Impairment and Neuroinflammation in an Oligomeric Aβ Induced Alzheimer's Disease Mouse Model Via Inhibition of Microglial Activation and NADPH Oxidase Expression.

A new strategy for Astragaloside IV in the treatment of diabetic kidney disease: Analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells

Astragaloside IV Ameliorates Cognitive Impairment and Protects Oligodendrocytes from Antioxidative Stress Via Regulation of the SIRT1/Nrf2 Signaling Pathway

Astragaloside IV Ameliorates Renal Injury in Streptozotocin-Induced Diabetic Rats Through Inhibiting NF-κB-mediated Inflammatory Genes Expression.

Ursolic acid mitigates cognitive dysfunction through amelioration of oxidative stress, inflammation and apoptosis in diabetic rats

Astragaloside IV Protects Against Diabetic Nephropathy Via Activating Enos in Streptozotocin Diabetes-Induced Rats

Proteomic and lipidomic analysis of the mechanism underlying astragaloside IV in mitigating ferroptosis through hypoxia-inducible factor 1α/heme oxygenase 1 pathway in renal tubular epithelial cells in diabetic kidney disease

Ginsenoside Re attenuates diabetes-associated cognitive deficits in rats

Study on Undercarboxylated Osteocalcin in Improving Cognitive Function of Rats with Type 2 Diabetes Mellitus by Regulating PI3K-AKT-GSK/3β Signaling Pathwaythrough medical images

Ginsenoside Rb1 Improves Cognitive Impairment Induced by Insulin Resistance through Cdk5/p35-NMDAR-IDE Pathway